Open-label, multicenter, observational, phase IV study to evaluate the adherence to treatment with 250mcg (8MIU) IFNB-1b [interferon-beta] (Betaseron) given subcutaneous every other day over a period of up to 12 months in patients with a first clinical demyelinating event suggestive of multiple sclerosis and patients with onset of relapsing-remitting multiple sclerosis (RRMS) within the past 12 months.

Trial Profile

Open-label, multicenter, observational, phase IV study to evaluate the adherence to treatment with 250mcg (8MIU) IFNB-1b [interferon-beta] (Betaseron) given subcutaneous every other day over a period of up to 12 months in patients with a first clinical demyelinating event suggestive of multiple sclerosis and patients with onset of relapsing-remitting multiple sclerosis (RRMS) within the past 12 months.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2010

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms START
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Planned number of patients changed from 125 to 104 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top